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Abstract
Biosimilars are products that contain a similar version of the active substance of an already authorized
original biologic medicinal product (reference medicinal product). Their development requires special con-
sideration, as similarity to the reference agent needs to be established through a comprehensive com-
parability exercise. Given the complex nature of these agents, minor structural differences may emerge,
but the process of biosimilarity determination is designed to ascertain that the nature and impact of these
differences are not clinically significant. Determination of biosimilarity should follow quality-by-design prin-
ciples, which provide a deep understanding of the product development process, guided by pre-defined
objectives, process control and risk management. Compared with novel biologic development, biosimilar
development places greater emphasis on establishing preclinical quality characteristics. Determination of
comparability of quality characteristics includes assessment of physicochemical properties, biological
activity, immunochemical properties, purity, impurity and quantity, with appropriate in vivo pharmacology
studies being conducted thereafter. Head-to-head comparisons are then conducted to determine phar-
macokinetic and pharmacodynamic characteristics, and efficacy, safety and tolerability in phase I and
phase III clinical studies. Post-approval risk management requirements include implementation of phar-
macovigilance systems and risk management through, for example, the conduct of pharmacoepidemio-
logical studies. There are several biosimilars used in the field of rheumatology that are available in the
European Union, or in development, that offer the potential to increase affordability/accessibility of biolo-
gical treatment. The role of these agents in rheumatology will be determined by the confidence placed in
them by rheumatologists. These prescribers should expect high-quality data evaluated by an extensive
assessment process.
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rheumatology
Rheumatology key messages
. A comprehensive process is applied to establish biosimilarity.
. Several biosimilar agents are currently licensed for use in rheumatology.
. The robust nature of the biosimilarity exercise is an important element when considering these agents.
Introduction
In recent years, we have seen an acceleration in scientific
research focused on molecular and cellular biology, which
has resulted in the successful development of many
biological agents (biologics) that have fundamentally
changed clinical practice. Biologics are drugs produced
by living cells that mimic the actions of natural endogen-
ous biological moieties [1] or, such as monoclonal antibo-
dies, that are directed against (and affect) particular
targets in the human body [2]. Their development has
provided clinicians with an alternative therapeutic strategy
to that provided by traditional small-chemical-molecule
therapeutics. Although biologics have revolutionized the
treatment of many chronic conditions [3], they are often
expensive in terms of cost per dose [4, 5]. The patent
expiry and loss of exclusivity of some of these innovative
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biologics has opened the door for the introduction of their
therapeutically equivalent alternatives, now commonly
known as biosimilars.
Generic copies of small-molecule-based therapeutics
have been widely used as alternatives to more expensive
branded agents. Indeed, a number of generic copies of
traditional small-chemical-molecule drugs, such as
statins, oral chemotherapeutics and antihistamines, have
been approved, based on evidence from relatively
small and inexpensive studies demonstrating bioequiva-
lence [5]. However, the manufacturing of biologics is
considerably more challenging than that for traditional
small-chemical-molecule drugs, as even relatively small
changes in an existing manufacturing process may
result in changes in efficacy or immunogenicity, making
the generic approach scientifically inappropriate for these
products. This has led to the development of the concept
of biosimilarity and the consequent extensive regulatory
approval pathways that are needed for physicochemical,
non-clinical and confirmatory clinical comparability [1].
Biosimilars are products that contain a similar version of
the active substance of an already authorized original bio-
logic medicinal product (the reference medicinal product)
whose data protection has expired [6]. Their development
requires special consideration, as similarity to the refer-
ence medicinal product needs to be established through
extensive comparability exercises in terms of quality char-
acteristics, biological activity, safety and efficacy [6]. This
approach needs to be comprehensive so that regulators
can review, and clinicians can prescribe, these agents
with confidence. The European Medicines Agency (EMA)
has taken the lead over the past 10 years in shaping the
environment, increasing understanding of comparability
and providing realistic expectations of the proof required
to confirm biosimilarity [68]. In this respect, the EMA has
developed guidelines, such as the overarching, quality,
non-clinical and class-specific guidelines on different
classes of biologics (including mAb) that support a de-
tailed understanding of what is required to thoroughly
evaluate biosimilarity [6, 8]; these are being constantly
revised and updated to reflect evolving knowledge and
cumulative experiences gained with the first generation
of biosimilars in Europe [6, 8].
Although the European Union (EU) biosimilar market is
relatively new, a preliminary analysis of pricing behaviour
indicates that biosimilars in some therapeutic areas are
priced below reference biologics, often with discounts of
525% [9]. The prospect of more affordable biosimilar
treatment options provides opportunities for health sys-
tems to expand access to biologics for more patients, to
free up valuable resources for investment in new areas and
to relieve the burden on healthcare budgets [10].
In addition, it is anticipated that the development and intro-
duction of a range of biosimilar medicines may generate
savings that can be reinvested in healthcare provision,
while at the same time driving pharmaceutical innovation
that ultimately improves outcomes for patients [10].
In this article, we review the concept of biosimilarity and
the regulatory requirements that are needed to establish
biosimilarity, as defined by the EMA. We also provide
examples of biosimilar agents for use in rheumatology
that have been subjected to this assessment and approval
process.
The concept of biosimilarity and the
rationale for its determination
The scientific concept of biosimilarity is well established,
and manufacturers need to ensure that sufficient analyses
are performed to demonstrate a high degree of similarity
between the reference agents and biosimilars prior to any
clinical testing [6, 11]. The EMA has extensive experience
in regulating and reviewing comparability exercises [68],
partly because the manufacturing processes of biologics
are often subject to modification, for example, to increase
efficiency [12]. Although not expected to be associated
with clinical consequences, these changes require an
analysis of pre- and post-change products (comparability
exercise), with subsequent approval by the EMA [6, 11].
Importantly, these alterations are made with knowledge of
the original manufacturing process, which differs from bio-
similar development where proprietary manufacturing
data are not available [13].
Most biologics are large complex proteins manufactured
using a living cell line in a highly controlled setting [14].
Even minor changes in their structure and conformation
may have an impact on their pharmaceutical properties,
pharmacodynamics (PD), safety or tolerability [11, 14]. For
example, conformational changes of mAb and receptorFc
fusion proteins can affect their binding affinity and
biological activity, which in turn may affect their pharmaco-
kinetics (PK) and PD profile, potentially having an impact on
their dosing regimen [15]. Furthermore, immunogenicity is
an important consideration, and thus should be borne in
mind as alterations in manufacturing processes and stor-
age conditions may potentially affect this aspect [11].
Antidrug antibodies could reduce circulating biologic
levels, cause a neutralizing antibody effect and/or adverse
reactions (e.g. infusion-related reactions) and may lead to a
loss of clinical efficacy [16, 17]. Consequently, the integrity
of the biosimilar needs to be assured to provide confidence
in its use.
The real challenge in biosimilar development is not in
determining whether differences exist compared with the
reference product, but whether these differences are clin-
ically relevant. Therefore, a comprehensive biosimilarity
exercise should cover almost all the structural and func-
tional characteristics of the reference molecule to assess
biosimilarity and to ensure that biosimilars have an
equivalent riskbenefit balance [6].
Building the evidence for biosimilarity
Biosimilars are characterized by their complex molecular
structure and cell culture manufacturing process, which
makes them more difficult to characterize, produce and
reproduce [18, 19], such that biosimilars and reference
biologics cannot be produced identically. Instead,
development is undertaken to establish physicochemical,
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biological and pharmacological critical quality attributes
(CQAs) that are intended to guide the clinical profile and
establish clinical comparability. CQAs are chemical, phys-
ical, biological and microbiological characteristics that
can be defined, measured and continually monitored to
ensure that the final product outputs remain within ac-
ceptable limits of quality. The process of establishing bio-
similarity should follow quality by design (QbD) principles.
QbD is a systematic approach to establish a deep under-
standing of the product development process that is
guided by predefined objectives and involves implemen-
tation of process control, based on sound science and
quality risk management [20].
When a manufacturer develops a new chemical or bio-
logical product, a well-established, step-wise approach is
taken to mitigate the risks of the product development
process and patient exposure. Similarly, biosimilar devel-
opment requires a number of steps, including selection of
an appropriate reference biologic, obtaining the reference
active pharmaceutical ingredient, identifying the quality
target product profile (QTPP) and CQAs of the reference
biologic, and developing a manufacturing process to
match the attributes of the reference biologic product
[18]. Although the concept of a biosimilar is applicable
to any biologic, the success of such a development ap-
proach will depend on the ability to characterize the ref-
erence product and therefore to demonstrate the similar
nature of the concerned products [21], using appropriately
available comparators [22]. The goal of biosimilar devel-
opment is to match the QTPP of the reference biologic
product and this should form the basis for the develop-
ment of the biosimilar, with the manufacturing process
being appropriately designed [23].
The evidence required to establish biosimilarity is gath-
ered using a step-wise approach, firstly establishing elem-
ents related to quality (physicochemical and biological
comparability), then pharmacology (non-clinical compar-
ability) and lastly clinical evaluation (clinical comparability)
[6, 24]. Quality comparability is established with regard to
the molecular structure as well as functionality, and must
be demonstrated with comprehensive analytical charac-
terization, relevant receptor-binding studies and bio-
assays, all of which should be performed with the
biosimilar and the reference product in a rigorous com-
parative manner [24]. The non-clinical and clinical com-
parability exercise, which is based on a head-to-head
comparison between the biosimilar and the reference
medicinal product, then provides the confidence that
any differences that might be observed at the quality
level have no impact on the safety and efficacy of the
biosimilar compared with the reference product [24].
Therefore, each step has a critical contribution to the
(bio)physical characteristics and should rely on the most
advanced state-of-the-art capabilities; no step can refute
or overcome significant differences in previous steps, and
all three steps must be satisfied to establish biosimilarity.
Given the above steps, the development of a biosimilar
can be as extensive as that of the original entity but with a
different emphasis (Fig. 1) [24]. Indeed, whereas there is a
much greater effort placed on establishing clinical efficacy
and tolerability for a new biologic agent (i.e. a positive
riskbenefit profile), much more emphasis is placed on
establishing comparability at the earlier stages of devel-
opment for a biosimilar. By focusing more closely on es-
tablishing analytical similarity, there is increased certainty
of a comparable clinical profile and a reduction in the
overall need for clinical testing [6].
Establishing physicochemical and
biological comparability
The majority of the work in establishing similarity is per-
formed preclinically, at which point any potential differ-
ences between the biosimilar and reference product are
more likely to be detected. In this respect, there are two
distinct areas on which regulators focus: the comparability
of the molecular characteristics and quality attributes of
the biosimilar and reference product, and the perform-
ance and consistency of the manufacturing process for
the biosimilar on its own [23]. This work involves in-
depth physicochemical and in vitro biological character-
ization of the biosimilar and comparison with the original
biologic to address structural, functional and immunogen-
icity concerns [11]. The biosimilarity analytical and quality
exercise should involve comprehensive analyses of the
proposed biosimilar and the reference agent using sensi-
tive and robust methods to determine not only similarities,
but also potential differences, in quality attributes [23].
Furthermore, bioanalytical assays should be appropriate
for their intended use and adequately validated [6].
Based on CQAs, key attributes to be evaluated and
compared for the biosimilar and reference agent include
physicochemical properties, biological activity, immuno-
chemical properties, purity and impurities, quantity and
strength (Fig. 2) [23]. The physicochemical comparison
comprises the evaluation of physicochemical parameters,
and should include a determination of the composition,
physical properties, and primary (amino-acid sequence)
and higher-order (e.g. local conformation and three-
dimensional) structures of the biosimilar [23]. The target
amino-acid sequence of the biosimilar, which is expected
to be the same as for the reference product, should be
confirmed, and the N- and C-terminal amino-acid se-
quences, free SH groups and disulfide bridges compared.
The presence and extent of post-translational modifica-
tions (e.g. glycosylation, oxidation, deamidation and
truncation) should also be characterized. Finally, if
present, carbohydrate structures, such as overall glycan
profile and site-specific glycosylation patterns, should be
compared [23]. Determination of biological activity is
dependent on the nature of the product, but would typic-
ally include receptorligand binding assays, enzymatic
assays, and cell-based and functional assays [23]. This
should include comparison of the immunological function
of monoclonal antibodies; generally, this would be done
by assessing the affinity of the products to the intended
target, binding of the Fc to the relevant receptors
(e.g. FcgR, C1q, FcRn) and induction of Fab- and Fc-
associated effector functions [8]. The purity and impurity
iv6 www.rheumatology.oxfordjournals.org
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profiles of the biosimilar and the reference product should
be determined and compared both qualitatively and quan-
titatively by a combination of analytical procedures.
The shelf-life of the reference product and any effect on
the quality profile should be accounted for. Process-
related impurities (e.g. host cell proteins, host cell DNA,
reagents, downstream impurities, etc.) should be deter-
mined and the potential risks related to these identified
impurities (e.g. immunogenicity) documented [23]. Finally,
quantity should be determined and a comparable strength
confirmed for the biosimilar and reference product.
The role of the manufacturing process
Against this background, the manufacturing process
should be tailored to the specific biosimilar and appropri-
ately designed to consistently achieve the key target quality
attributes, or QTPP, of the reference biologic product [23].
As the characteristics of a biologic can change over time,
as a result of operational variations within a manufacturing
process or following storage [25], testing multiple lots of a
reference biologic over a period of time is required to build a
complete picture of the QTPP and to ensure that the design
of a manufacturing process produces a biosimilar that clo-
sely reflects the reference biologic product [23]. The formu-
lation of the biosimilar does not need to be identical to that of
the reference agent; however, it does need to be appropriate
with regard to the originator’s pharmaceutical profile. For
example, regardless of the formulation selected, suitability
should be determined with regard to the stability, compati-
bility, integrity, activity and strength of the active substance.
If a different formulation/closure system from the reference
biologic product is used, its potential impact on the efficacy
and safety of the biosimilar also needs to be justified [23].
Establishing non-clinical in vivo biosimilarity
The use of animals in research remains a controversial
subject in the wider community. Guidelines recognize
this concern and recommend that the use of animals
should be minimized or eliminated where possible—for
example, by implementing the principles of the 3Rs
FIG. 1 Major elements and emphasis in the development of a biosimilar
Information taken from [24].
FIG. 2 Key steps in the analytical exercise to establish biosimilarity
Information taken from [23]. FcgR: Fc (gamma) receptor; FcRn: neonatal Fc (fragment crystallizable) receptor; PK:
pharmacokinetics.
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(Replacement, Reduction and Refinement) for humane
animal research. However, non-clinical evaluation using
in vivo studies may be necessary to complement informa-
tion gathered during the analytical phase of biosimilar de-
velopment [6]. In particular, the need for non-clinical
in vivo studies may be prompted by the presence of po-
tentially relevant quality attributes that have not been de-
tected in the reference product, the presence of
potentially relevant quantitative differences in quality attri-
butes between the biosimilar and the reference product,
and any relevant differences in formulation, for example,
use of excipients not widely used for biotechnology-
derived proteins [6].
In vivo studies
If an in vivo evaluation is deemed to be necessary, then the
focus of the study/studies will depend on the need for
additional information [6]. Assessment may include quan-
titative comparison of the PK and PD profiles of the bio-
similar and reference product, including doseconcentration
response [6]. For safety studies, a flexible approach should
be considered, particularly if non-human primates are the
only relevant species [6]. The conduct of toxicity studies in
non-relevant species (i.e. to assess non-specific toxicity
only, based on impurities) and standard repeated dose-tox-
icity studies in non-human primates is not recommended
[26]. However, if justified, a repeated dose-toxicity study
with refined design (e.g. single dose level, one gender) or
an in-life evaluation of safety parameters (e.g. clinical signs,
body weight and vital functions) may be considered [6].
Quantitative and qualitative differences in product-related
variants (e.g. glycosylation), which may give rise to hyper-
sensitivity, should be evaluated clinically [6]. Although im-
munogenicity studies in animals are not predictive of
immunogenicity in humans, blood samples may be taken
in animal studies for future evaluations of PK/toxicokinetic
data, if required [6]. Studies of safety pharmacology, repro-
ductive toxicology and carcinogenicity are not required [6].
Similarly, studies on local tolerance are generally not
required; however, if excipients for which there is little infor-
mation in relation to the route of administration are intro-
duced, local tolerance may need to be assessed (e.g. as
part of other non-clinical in vivo studies) [6].
The confirmatory role of clinical phase I and
phase III studies
As discussed previously, the majority of work in estab-
lishing biosimilarity focuses on preclinical, and particu-
larly quality, aspects of the biosimilar. This emphasis
allows for greater certainty that the clinical profile of the
biosimilar and reference biologic are comparable,
thereby reducing the need for clinical evaluation. When
required, clinical biosimilarity studies are conducted in a
step-wise approach, starting with PK, and then (if feas-
ible) PD (phase I) evaluations, followed by clinical effi-
cacy and safety (phase III) studies. However, in some
cases (and according to updated EMA guidelines), con-
firmatory PK and PD studies may suffice to establish
clinical biosimilar compatibility [6, 27]. Clinical studies
are generally conducted using the manufactured
formulation, but if this is not feasible, appropriate sup-
porting data should be generated [6]; for example, com-
parison of investigational and manufactured formulations
that may vary.
Pharmacokinetic and pharmacodynamic phase I studies
Comparative PK studies designed to demonstrate the
similar PK profile of the biosimilar and the reference prod-
uct are an essential element of the biosimilarity exercise
[6, 28]. The design of the PK study depends on a number
of factors, including clinical context, safety and the PK of
the reference agent and should be defined and justified
prior to conducting the study [6, 28]. Although a single-
dose, cross-over study, with full characterization of the PK
profile, including the late elimination phase, is preferred
[6], the ordinary cross-over design is not appropriate for
therapeutic proteins with a long half-life—for example,
therapeutic antibodies and pegylated proteins, or for pro-
teins for which the formation of anti-drug antibodies is
likely [28]. In such cases, a parallel-group design may be
necessary, with emphasis placed on minimizing the risk
for potential imbalance between the groups [28]. If part of
the PK information is gathered from healthy volunteers,
the validity of extrapolation of that information to the
target population needs to be addressed. This is because
elimination for some products is largely dependent on
target receptor uptake, meaning that differences in recep-
tor density between healthy volunteers and the target
population can create some important PK differ-
ences—for example, in half-life [28].
PK evaluations for biosimilars include absorption, dis-
position, dosetime dependency and binding to blood
components. In vivo studies should be conducted in
healthy volunteers or patients to describe the absorption
characteristics of the compound (e.g. extent and rate)
unless the IV route is exclusively used [28]. Single-dose
studies are generally sufficient to characterize absorption
and to compare different administration routes [28].
As soluble receptors may bind to the therapeutic protein,
resulting in an altered PK profile through changed clear-
ance or volume, this potential effect should be examined
[28]. Likewise, the binding capacity to plasma proteins
(albumin, a-acid glycoprotein) should be studied when
relevant. When conducting these PK evaluations, it is im-
portant to give due consideration to a number of factors,
including chemical modification of proteins, inter-subject
variability (e.g. demographic factors such as age and
weight), immunogenicity, drugdrug interactions and spe-
cial populations (e.g. patients with renal or hepatic impair-
ment) [28].
It is also necessary to evaluate the PKPD relationship,
and PD markers of clinical relevance can be added to PK
studies to cover this requirement [6]. In certain cases,
comparative PK/PD studies may be sufficient to demon-
strate clinical comparability, provided that the following
conditions are met: (1) the selected PD biomarker is an
accepted surrogate marker for clinical outcome and com-
parability has been shown in this respect; (2) a PD marker
is chosen that is not an established surrogate for clinical
outcome, but is relevant to the PD action of the agent and
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a doseresponse relationship has been established,
meaning that a single or multiple doseresponse study
may be sufficient to waive a clinical efficacy study; (3)
the body of evidence from the analytical exercise and
phase I PK/PD study may provide sufficiently robust evi-
dence for clinical comparability [6]. If evidence to establish
clinical biosimilar comparability is to be derived solely
from PK studies, supported by studies with a non-
surrogate PD marker/biomarker, a proposal for the size
of the equivalence margin(s) with its clinical justification,
as well as measures for demonstration of a comparable
safety profile, is required [6].
Efficacy studies
The aim of phase III biosimilarity trials is not to establish
efficacy per se, but to demonstrate comparable clinical
performance [6]. The EMA Committee for Medicinal
Products for Human Use has issued disease-specific
guidelines on the development of novel agents [29], and
where appropriate, product-class-specific guidelines for
biosimilars in some areas [6]. In general, comparable
clinical efficacy should be established in adequately pow-
ered, randomized, parallel-group (preferably double-blind)
trials, using an equivalence design [6]. The use of a non-
inferiority design is considered to be less acceptable, but
may be justified on the basis of a strong scientific rationale
and taking into consideration the characteristics of the
reference product, for example, safety/tolerability profile
and dose range [6]. A non-inferiority trial may only be ac-
cepted where the possibility of significant and clinically
relevant increases in efficacy can be excluded on scien-
tific and mechanistic grounds [6]. The study population
should be representative of those included in the
approved indication for the reference agent, and should
be sufficiently sensitive to detect potential differences be-
tween the biosimilar and the reference product [6].
Occasionally, changes in clinical practice may require a
deviation from the most sensitive approved therapeutic
indication, for example, in terms of concomitant medica-
tion used in a combination treatment, line of therapy or
severity of the disease [6]. If a correlation has been
demonstrated between the hard clinical endpoints recom-
mended by the guidelines for new active substances and
other clinical/PD endpoints that are more sensitive for de-
tecting clinically meaningful differences in previous clinical
trials with the reference product, it is not necessary to use
the same primary efficacy endpoints as those that were
used in the marketing authorization application of the ref-
erence product. However, it is advisable to include a se-
lection of common endpoints (e.g. as secondary
endpoints) to facilitate comparisons to the clinical trials
conducted with the reference product [6].
Safety evaluation
Building knowledge of the safety profile of the biosimilar is
a very important aspect of the exercise. As with any
new biologic, the safety profile of the biosimilar is cap-
tured throughout the clinical programme, during phase
I PK/PD studies and in head-to-head phase III compara-
tive studies [6]. As with any safety evaluation, the nature,
severity and frequency of adverse events are evaluated,
with adverse events between the biosimilar and the refer-
ence product being critically compared. In particular,
consideration is given to any safety concerns that may
arise from differences in the manufacturing process [6].
Furthermore, because of the potential immunogenic
nature of biological agents, immunogenicity and infusion-
related reactions are closely monitored and comparative
studies conducted to assess comparative immunogenicity
[6, 30, 31]. The duration of the immunogenicity study
should be justified on a case-by-case basis, depending
on the duration of the treatment course, clearance of the
product from the circulation and the time for emergence of
a humoral immune response [6]. Increased immunogenicity
compared with the reference product may become an
issue for the benefitrisk analysis and would question bio-
similarity. However, a lower immunogenicity profile for the
biosimilar would not preclude approval as a biosimilar [6].
Post-approval risk management requirements
Use of drugs in the wider clinical community and for
longer periods of time may prompt the emergence of
rare or concerning adverse reactions [11] that have not
been identified during the biosimilar clinical develop-
ment programme [6]. For this reason, the clinical
safety of biosimilars must be monitored closely on an
ongoing basis during the post-approval phase to ensure
patient safety [6, 24]. To do this, a pharmacovigilance
system and risk management plan should be devised,
taking into account the identified and possible risks,
with immunogenicity being given particular attention
[6]. Elements of pharmacovigilance and risk manage-
ment may include safety monitoring applied to the ref-
erence compound or class, participation in new or
existing pharmacoepidemiological studies (e.g. for the
reference compound) and risk minimization activities
applied to the reference compound [6]. Physicians
reporting adverse events should provide as much infor-
mation as possible, noting the specific agent, event and
its occurrence linked to source identity, such as brand
name and batch number [6, 11]. Such an approach is
particularly important when considering the emergence
of adverse reactions in relation to switching between
reference and biosimilar agents [11].
Overview of biosimilar agents for rheumatology in
the EU
DMARDs are the mainstay of rheumatic disease (RD) ther-
apy [32]. The development of conventional synthetic
DMARDs (csDMARDs) was followed by the development
of TNF inhibitors, the first biological DMARDs (bDMARDs)
that were introduced into rheumatology [32]. Today, five
different TNF inhibitors (infliximab, adalimumab, etaner-
cept, certolizumab and golimumab) are approved for
use in RD. Following TNF inhibitors, new bDMARDs with
different modes of action were developed: abatacept, tar-
geting the co-stimulation between T and B cells; rituxi-
mab, targeting CD20+ B cells; and tocilizumab, an IL-6
receptor antagonist. Although bDMARDS have been
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shown to have notable efficacy, they are costly [33].
Consequently, not all patients who are eligible are pre-
scribed these drugs, with preference generally being
given to patients with more severe and aggressive disease
[34]. Cost containment can however be achieved with
bDMARDs. For example, rituximab is a cost-effective al-
ternative to TNF inhibitors during the early course of the
disease [35] and bDMARD dose reductions or stoppages
of550% can be achieved [3638], which would translate
into significant cost reductions and wider possible choice.
Alternative strategies to delay or mitigate bDMARD imple-
mentation include a treat-to-target (or tight control) ap-
proach with combination csDMARDs [3941], and use of
combination csDMARDs following inadequate response
to csDMARD therapy [42, 43].
As of March 2017, there are four biosimilar medicines
that have received approval and are available on the
market for patients with RDs in the EU (overviewed in
detail in the third article of this supplement, by
Schulze-Koops and Skapenko). These comprise two
biosimilar versions of infliximab, one of which (CT-P13)
is available under two brand names, that is, Inflectra

and Remsima

(manufactured by Celltrion Inc.), and
one (SB2) under the brand name Flixabi

(manufactured
by Biogen). An etanercept biosimilar (SB4) is available
under the brand name Benepali

(manufactured by
Biogen). Flixabi

, Inflectra

and Remsima

are approved
for use in RA, adult and pediatric Crohn’s disease, adult
and pediatric ulcerative colitis, AS, PsA and psoriasis
[4446]. Benepali

is approved for the treatment of
adults with RA, PsA, axial spondyloarthritis (AS and
non-radiographic axial spondyloarthritis) and plaque
psoriasis [47]. Recently, the EMA Committee for
Medicinal Products for Human Use has adopted a posi-
tive opinion on the type II variation application for the
indication extension of Benepali

for the treatment of
JIA and pediatric plaque psoriasis in patients weighing
>62.5 kg [48]. There are currently some 41 biosimilar
medicines for RD in the pipeline for four key reference
biologics (adalimumab, etanercept, infliximab and ritux-
imab) [10]; of these, a number (including those already
approved) have had data published in peer-reviewed
journals or presented at international scientific meetings
(Table 1) [49].
Discussion
The pathway for the development and approval of bio-
similiars has been well established by the EMA. This
development process follows a step-wise approach,
with greater emphasis placed on quality assessment
and lesser emphasis on clinical assessment than for de
novo biologics. This is because proof of biosimilarity lar-
gely rests with the molecular and preclinical profile,
removing the onus from the clinical pathway, for which
only equivalence testing may be required. Rigorous evalu-
ations are followed to establish biosimilarity, and further
risk assessment protocols are instigated following author-
ization. The extensive nature of the biosimilarity approval
process emphasizes the quality of the dataset for existing
biosimilar agents. This is an important factor when phys-
icians are faced with greater therapeutic choice that can
be tailored to patient need; greater physician confidence
in prescribing additional agents may well lead to greater
patient-tailored care.
More than 80 biologic molecules have been launched
globally over the past decade, bringing new treatment op-
tions to patients across a large number of therapy areas
[10]. Indeed, across the EU, the use of erythropoietins,
granulocytecolony stimulating factors and human
growth hormone have all increased following the launch
of biosimilar versions. The development of biobetter
agents, preferably called next-generation biologics, is
also a hot topic under discussion [5052]. Next generation
biologics are versions of existing biologics that have been
modified (e.g. through introduction of a different glycosy-
lation profile or through pegylation) to have enhanced
properties, such as improved effector function or elimin-
ation half-life [53]. The development and possible avail-
ability of these agents will provide further choice in this
therapeutic area.
To date, four biosimilar agents are available for use in
rheumatology, and it is envisaged that they will play an
important role in the management of autoimmune RDs by
TABLE 1 Biosimilars for rheumatic diseases for which
data have been published in peer-reviewed journals or
presented at international scientific meetings
Reference
product
Biosimilars for rheumatic diseases
(published or presented data)
Adalimumab ABP 501b
BI 695501
CHS-1420
GP-2017
M923
SB5
ZRC-3197 (Exemptia

)
PF-06410293
Etanercept AVG01
CHS-0214
GP2015a,b
HD203
LBEC0101
SB4 (Benepali

)a
Infliximab BOW015
CT-P13 (Inflectra

; Remsima

)a,b
PF-06438179
SB2 (Flixabi

)a
Rituximab CT-P10
GP2013
PF-05280586
Reproduced from: Ann Rheum Dis. The role of biosimilars in
the treatment of rheumatic diseases, Do¨rner T, Strand V,
Cornes P et al. 72:3228, !2013 [49]. With permission
from BMJ Publishing Group Ltd. aEMA approved. bFDA
approved. EMA: European Medicines Agency; FDA: Food
and Drug Administration.
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helping to reduce costs, thereby improving patient ac-
cess to treatment [54, 55]. Moreover, lower costs may
also encourage earlier implementation of biologic therapy
[56, 57], although further evidence from clinical trials, par-
ticularly observational studies, is required. Several other
biosimilar agents for use in rheumatology are currently in
development, offering further potential to increase afford-
ability of treatment and improve accessibility [10]. The role
of these biosimilars in rheumatology will ultimately be
determined by the confidence placed in them by rheuma-
tologists, and these prescribers should expect high-
quality data, generated in a manner required by leading
regulatory authorities such as the EMA and produced by
manufacturers with pertinent expertise.
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